U.S. Markets open in 3 hrs 32 mins

InMed Pharmaceuticals Inc. (IN.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
4.7400+0.3300 (+7.48%)
At close: 3:55PM EDT

InMed Pharmaceuticals Inc.

815 West Hastings Street
Suite 310
Vancouver, BC V6C 1B4
604 669 7207

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Eric A. AdamsPres, CEO & Director387.7kN/A1964
Mr. Bruce S. Colwill C.A., CPA, CACFO & Corp. Sec.273.15kN/A1965
Ms. Alexandra D. J. ManciniSr. VP of Clinical & Regulatory Affairs311kN/A1953
Dr. Eric Chih-Hsien HsuSr. VP of Preclinical R&D300.7kN/A1970
Mr. Michael Woudenberg P.Eng.VP of Chemistry, Manufacturing & Controls287.6kN/A1967
Dr. Sazzad HossainCo-FounderN/AN/AN/A
Mr. Brendan PayneDirector of Investor RelationsN/AN/AN/A
Mr. Richard HoyVP of Sales & MarketingN/AN/AN/A
Dr. Ado MuhammadSr. Consultant of Medical AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Corporate Governance

InMed Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.